Caution is advised whenever VIRACEPT is co- administered with medicinal products which are inducers or inhibitors and/ or substrates of CYP3A4; such combinations may require dose adjustment (see also sections 4.3, 4.5 and 4.8).
Selliste kombinatsioonide korral võib osutuda vajalikuks annuse kohandamine (vt ka lõigud 4. 3, 4. 5 ja 4. 8).